{"id":"NCT01421511","sponsor":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","briefTitle":"TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections","officialTitle":"A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of IV to Oral 6-Day TR-701 Free Acid and IV to Oral 10-Day Linezolid for the Treatment of ABSSSI","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09-15","primaryCompletion":"2013-01-10","completion":"2013-01-10","firstPosted":"2011-08-22","resultsPosted":"2014-09-08","lastUpdate":"2018-08-29"},"enrollment":666,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Skin and Subcutaneous Tissue Bacterial Infections"],"interventions":[{"type":"DRUG","name":"TR-701 FA","otherNames":[]},{"type":"DRUG","name":"Linezolid","otherNames":[]}],"arms":[{"label":"TR-701 FA","type":"EXPERIMENTAL"},{"label":"Linezolid","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to oral TR-701 FA 200 mg once daily for 6 days versus IV to oral ZyvoxÂ® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults. Patients are to start treatment with at least 2 IV doses and may receive IV therapy for the entire treatment duration.\n\nApproximately 100 to 140 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment.","primaryOutcome":{"measure":"The Early Clinical Response Rate","timeFrame":"48-72 hours","effectByArm":[{"arm":"Tedizolid Phosphate","deltaMin":283,"sd":null},{"arm":"Linezolid","deltaMin":276,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":117,"countries":["United States","Argentina","Australia","Brazil","Germany","Mexico","New Zealand","Poland","Russia","South Africa","Spain"]},"refs":{"pmids":["28264845","28003218","27530088","25421472","25246392","24909499"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":331},"commonTop":["Nausea","Headache","Diarrhoea","Vomiting","Abscess"]}}